(Q34070854)

30 July 2017

1 reference

title

Levodopa motor complications in Parkinson's disease (English)

1 reference

30 July 2017

1 reference

1 reference

Obeso JA

1

1 reference

30 July 2017

Olanow CW

series ordinal

2

1 reference

30 July 2017

Nutt JG

series ordinal

3

1 reference

30 July 2017

publication date

1 October 2000

1 reference

30 July 2017

published in

Trends in Neurosciences

1 reference

30 July 2017

volume

23

1 reference

30 July 2017

issue

10 Suppl

1 reference

30 July 2017

page(s)

S2-7

1 reference

An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Aromatic Amino Acids and Modification of Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Success and problems of long-term levodopa therapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

A radical hypothesis for neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Risk factors for levodopa-induced dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Motor fluctuations in Parkinson's disease: pathophysiology and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Young onset Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Long-term side-effects of levodopa.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Pargyline Prevents MPTP-Induced Parkinsonism in Primates

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Motor response to apomorphine and levodopa in asymmetric Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Posteroventral medial pallidotomy in advanced Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Primate models of movement disorders of basal ganglia origin

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

Continuous dopamine-receptor stimulation in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900031-8

7 January 2021

10.1016/S1471-1931(00)00031-8

Identifiers

DOI

1 reference

30 July 2017

1 reference